These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 28350120)

  • 1. Cross-validation of genes potentially associated with overall survival and drug resistance in ovarian cancer.
    Gao Y; Liu X; Li T; Wei L; Yang A; Lu Y; Zhang J; Li L; Wang S; Yin F
    Oncol Rep; 2017 May; 37(5):3084-3092. PubMed ID: 28350120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microarray-based identification of genes associated with prognosis and drug resistance in ovarian cancer.
    Yin F; Yi S; Wei L; Zhao B; Li J; Cai X; Dong C; Liu X
    J Cell Biochem; 2019 Apr; 120(4):6057-6070. PubMed ID: 30335894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Downregulation of transient receptor potential cation channel, subfamily C, member 1 contributes to drug resistance and high histological grade in ovarian cancer.
    Liu X; Zou J; Su J; Lu Y; Zhang J; Li L; Yin F
    Int J Oncol; 2016 Jan; 48(1):243-52. PubMed ID: 26647723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NCALD affects drug resistance and prognosis by acting as a ceRNA of CX3CL1 in ovarian cancer.
    Dong C; Yin F; Zhu D; Cai X; Chen C; Liu X
    J Cell Biochem; 2020 Nov; 121(11):4470-4483. PubMed ID: 32030795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microarray-based identification of genes associated with cancer progression and prognosis in hepatocellular carcinoma.
    Yin F; Shu L; Liu X; Li T; Peng T; Nan Y; Li S; Zeng X; Qiu X
    J Exp Clin Cancer Res; 2016 Aug; 35(1):127. PubMed ID: 27567667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of microarray-identified genes associated with ovarian cancer progression.
    Liu X; Gao Y; Zhao B; Li X; Lu Y; Zhang J; Li D; Li L; Yin F
    Int J Oncol; 2015; 46(6):2467-78. PubMed ID: 25891226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Upregulation of CALD1 predicted a poor prognosis for platinum-treated ovarian cancer and revealed it as a potential therapeutic resistance target.
    Li W; Huang L; Qi N; Zhang Q; Qin Z
    BMC Genomics; 2024 Feb; 25(1):183. PubMed ID: 38365611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low expression of KCNN3 may affect drug resistance in ovarian cancer.
    Liu X; Wei L; Zhao B; Cai X; Dong C; Yin F
    Mol Med Rep; 2018 Aug; 18(2):1377-1386. PubMed ID: 29901154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of microarray-identified genes and microRNAs associated with drug resistance in ovarian cancer.
    Zou J; Yin F; Wang Q; Zhang W; Li L
    Int J Clin Exp Pathol; 2015; 8(6):6847-58. PubMed ID: 26261572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prognostic values of the peroxiredoxins family in ovarian cancer.
    Li S; Hu X; Ye M; Zhu X
    Biosci Rep; 2018 Oct; 38(5):. PubMed ID: 30104402
    [No Abstract]   [Full Text] [Related]  

  • 11. Establishment of a SVM classifier to predict recurrence of ovarian cancer.
    Zhou J; Li L; Wang L; Li X; Xing H; Cheng L
    Mol Med Rep; 2018 Oct; 18(4):3589-3598. PubMed ID: 30106117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells.
    Okamoto A; Nikaido T; Ochiai K; Takakura S; Saito M; Aoki Y; Ishii N; Yanaihara N; Yamada K; Takikawa O; Kawaguchi R; Isonishi S; Tanaka T; Urashima M
    Clin Cancer Res; 2005 Aug; 11(16):6030-9. PubMed ID: 16115948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Machine learning and bioinformatics models to identify gene expression patterns of ovarian cancer associated with disease progression and mortality.
    Hossain MA; Saiful Islam SM; Quinn JMW; Huq F; Moni MA
    J Biomed Inform; 2019 Dec; 100():103313. PubMed ID: 31655274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Noncoding RNA (ncRNA) Profile Association with Patient Outcome in Epithelial Ovarian Cancer Cases.
    Oliveira DVNP; Prahm KP; Christensen IJ; Hansen A; Høgdall CK; Høgdall EV
    Reprod Sci; 2021 Mar; 28(3):757-765. PubMed ID: 33125686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive Analysis of the Expression and Prognosis for Laminin Genes in Ovarian Cancer.
    Diao B; Yang P
    Pathol Oncol Res; 2021; 27():1609855. PubMed ID: 34512203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A random forest classifier predicts recurrence risk in patients with ovarian cancer.
    Cheng L; Li L; Wang L; Li X; Xing H; Zhou J
    Mol Med Rep; 2018 Sep; 18(3):3289-3297. PubMed ID: 30066910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathway analysis of gene lists associated with platinum-based chemotherapy resistance in ovarian cancer: the big picture.
    Helleman J; Smid M; Jansen MP; van der Burg ME; Berns EM
    Gynecol Oncol; 2010 May; 117(2):170-6. PubMed ID: 20132968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic values of
    Chetry M; Li S; Liu H; Hu X; Zhu X
    Biosci Rep; 2018 Apr; 38(2):. PubMed ID: 29472315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unsupervised analysis reveals two molecular subgroups of serous ovarian cancer with distinct gene expression profiles and survival.
    Lisowska KM; Olbryt M; Student S; Kujawa KA; Cortez AJ; Simek K; Dansonka-Mieszkowska A; Rzepecka IK; Tudrej P; Kupryjańczyk J
    J Cancer Res Clin Oncol; 2016 Jun; 142(6):1239-52. PubMed ID: 27028324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated expression of Tweety homologue 3 predicts poor clinical outcomes in ovarian cancer.
    Zhou J; Xu Y; Chen X; Chen F; Zhang J; Zhu X
    J Cancer; 2021; 12(23):7147-7157. PubMed ID: 34729116
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.